{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T21:45:50Z","timestamp":1780436750442,"version":"3.54.1"},"reference-count":30,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T00:00:00Z","timestamp":1597276800000},"content-version":"unspecified","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Turnstone Biologics"},{"DOI":"10.13039\/501100002655","name":"Terry Fox Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004203","name":"Ontario Institute for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004203","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015545","name":"Seerave Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015545","id-type":"DOI","asserted-by":"crossref"}]},{"name":"SIRIC Cancer Research and Personalized Medicine"},{"name":"BioCanRx"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2020,7,22]]},"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:p>Despite a sizeable body of research, the efficacy of therapeutic cancer vaccines remains limited when applied as sole agents. By using a prime:boost approach involving two viral cancer vaccines, we were able to generate large tumor-specific CD8<jats:sup>+<\/jats:sup> T-cell responses in a murine model of disseminated pulmonary melanoma. Significant increases in the number and quality of circulating effector T-cells were documented when low-dose cyclophosphamide (CTX) was administered pre-vaccination to tumor-bearing but not tumor-free hosts. Interestingly, tumor-bearing mice receiving CTX and co-primed with a melanoma differentiation antigen together with an irrelevant control antigen exhibited significantly enhanced immunity against the tumor, but not the control antigen, in secondary lymphoid organs. This result highlighted an increased cancer-specific reactivity of vaccine-induced T-cell responses following CTX preconditioning. Additionally, an acute reduction of the frequency of peripheral regulatory T-cells (Tregs) was noticeable, particularly in the proliferating, presumably tumour-reactive, subset. Enhanced infiltration of lungs with multifunctional T-cells resulted in overt reduction in metastatic burden in mice pretreated with CTX. Despite doubling the median survival in comparison to untreated controls, most vaccinated mice ultimately succumbed to cancer progression. However, preconditioning of the virus-based vaccination with CTX resulted in a remarkable improvement of the therapeutic activity leading to complete remission in the majority of the animals. Collectively, these data reveal how CTX can potentiate specific cellular immunity in an antigen-restricted manner that is only observed in vaccinated tumor-bearing hosts while depleting replicating Tregs. A single low dose of CTX enhances antitumor immunity and the efficacy of this potent prime:boost platform by modulating the kinetics of the vaccine-specific responses. Clinical assessment of CTX combined with next-generation cancer vaccines is indicated.<\/jats:p>","DOI":"10.1136\/jitc-2020-000981","type":"journal-article","created":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T10:42:54Z","timestamp":1597401774000},"page":"e000981","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":25,"title":["Enhanced immunotherapeutic profile of oncolytic virus-based cancer vaccination using cyclophosphamide preconditioning"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8355-7562","authenticated-orcid":false,"given":"Jonathan G","family":"Pol","sequence":"first","affiliation":[{"name":"McMaster Immunology Research Center, Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada"},{"name":"Equipe 11 labellis\u00e9e Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France"},{"name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), U1138, Paris, France"},{"name":"Gustave Roussy Cancer Campus, Villejuif, France"},{"name":"Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J","family":"Atherton","sequence":"additional","affiliation":[{"name":"McMaster Immunology Research Center, Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle B","family":"Stephenson","sequence":"additional","affiliation":[{"name":"McMaster Immunology Research Center, Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byram W","family":"Bridle","sequence":"additional","affiliation":[{"name":"Department of Pathobiology, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel T","family":"Workenhe","sequence":"additional","affiliation":[{"name":"McMaster Immunology Research Center, Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Kazdhan","sequence":"additional","affiliation":[{"name":"McMaster Immunology Research Center, Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AJ Robert","family":"McGray","sequence":"additional","affiliation":[{"name":"McMaster Immunology Research Center, Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghong","family":"Wan","sequence":"additional","affiliation":[{"name":"McMaster Immunology Research Center, Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Kroemer","sequence":"additional","affiliation":[{"name":"Equipe 11 labellis\u00e9e Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France"},{"name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), U1138, Paris, France"},{"name":"Gustave Roussy Cancer Campus, Villejuif, France"},{"name":"Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France"},{"name":"Sorbonne Universit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian D","family":"Lichty","sequence":"additional","affiliation":[{"name":"McMaster Immunology Research Center, Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,8,13]]},"reference":[{"key":"2025100314231552000_8.2.e000981.1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-407190-2.00007-1"},{"key":"2025100314231552000_8.2.e000981.2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.16"},{"key":"2025100314231552000_8.2.e000981.3","doi-asserted-by":"publisher","DOI":"10.1172\/JCI80009"},{"key":"2025100314231552000_8.2.e000981.4","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/nbt.3690","article-title":"Rekindling cancer vaccines","volume":"34","author":"Branca","year":"2016","journal-title":"Nat Biotechnol"},{"key":"2025100314231552000_8.2.e000981.5","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0102"},{"key":"2025100314231552000_8.2.e000981.6","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.98"},{"key":"2025100314231552000_8.2.e000981.7","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.249"},{"key":"2025100314231552000_8.2.e000981.8","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1600106"},{"key":"2025100314231552000_8.2.e000981.9","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1111\/ajt.14238","article-title":"Chemotherapy and transplantation: the role of immunosuppression in malignancy and a review of antineoplastic agents in solid organ transplant recipients","volume":"17","author":"Krisl","year":"2017","journal-title":"American Journal of Transplantation"},{"key":"2025100314231552000_8.2.e000981.10","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0048"},{"key":"2025100314231552000_8.2.e000981.11","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2012-3439"},{"key":"2025100314231552000_8.2.e000981.12","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-011-0245-0"},{"key":"2025100314231552000_8.2.e000981.13","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1103782108"},{"key":"2025100314231552000_8.2.e000981.14","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2009.146"},{"key":"2025100314231552000_8.2.e000981.15","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-0283"},{"key":"2025100314231552000_8.2.e000981.16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087831","article-title":"Quantification of B16 melanoma cells in lungs using triplex Q-PCR--a new approach to evaluate melanoma cell metastasis and tumor control","volume":"9","author":"Sorensen","year":"2014","journal-title":"PLoS One"},{"key":"2025100314231552000_8.2.e000981.17","first-page":"Unit 20.1","article-title":"B16 as a mouse model for human melanoma","volume":"Chapter 20","author":"Overwijk","year":"2001","journal-title":"Curr Protoc Immunol"},{"key":"2025100314231552000_8.2.e000981.18","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ejro.2019.02.003","article-title":"The clinical significance of indeterminate pulmonary nodules in melanoma patients at baseline and during follow-up chest CT","volume":"6","author":"Soliman","year":"2019","journal-title":"Eur J Radiol Open"},{"key":"2025100314231552000_8.2.e000981.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2006.08.065"},{"key":"2025100314231552000_8.2.e000981.20","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0022-5223(19)34957-8","article-title":"Analysis of 945 cases of pulmonary metastatic melanoma","volume":"103","author":"Harpole","year":"1992","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2025100314231552000_8.2.e000981.21","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-007-0305-4"},{"key":"2025100314231552000_8.2.e000981.22","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-012-1322-5"},{"key":"2025100314231552000_8.2.e000981.23","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0408197102"},{"key":"2025100314231552000_8.2.e000981.24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00608-2"},{"key":"2025100314231552000_8.2.e000981.25","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.pathol.2015.12.006","article-title":"Tumour-infiltrating lymphocytes in melanoma prognosis and\u00a0cancer\u00a0immunotherapy","volume":"48","author":"Lee","year":"2016","journal-title":"Pathology"},{"key":"2025100314231552000_8.2.e000981.26","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1067745","article-title":"Long-lasting multifunctional CD8+ T cell responses in end-stage melanoma patients can be induced by dendritic cell vaccination","volume":"5","author":"Wimmers","year":"2015","journal-title":"Oncoimmunology"},{"key":"2025100314231552000_8.2.e000981.27","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/cas.13193","article-title":"A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer","volume":"108","author":"Shirahama","year":"2017","journal-title":"Cancer Sci"},{"key":"2025100314231552000_8.2.e000981.28","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2883"},{"key":"2025100314231552000_8.2.e000981.29","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1445459","article-title":"Transforming the prostatic tumor microenvironment with oncolytic virotherapy","volume":"7","author":"Atherton","year":"2018","journal-title":"Oncoimmunology"},{"key":"2025100314231552000_8.2.e000981.30","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1512329","article-title":"Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials","volume":"8","author":"Pol","year":"2019","journal-title":"Oncoimmunology"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2020-000981","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T21:23:23Z","timestamp":1759526603000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-000981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,8,13]]},"published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1136\/jitc-2020-000981"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2020-000981","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8]]}}}